Baxter International Inc. · NYSE:BAX

Baxter International — Investor Presentation (November 2024)

14 slides from Baxter International's investor presentation, Nov 7, 2024

  1. Slide 1: Supplemental Historical Financial Information

    SUPPLEMENTAL HISTORICAL FINANCIAL INFORMATION N ove m b e r 7 , 2 0 24 1

  2. Slide 2: Non-GAAP Financial Measures

    NON-GAAP FINANCIAL MEASURES This presentation contains certain financial measures that are not calculated in accordance with U.S. GAAP (Generally Accepted Accounting Principles). The non-GAAP financial measures include sales growth (on a constant currency), adjusted gross margin, adjusted selling, g

  3. Slide 3: Impact of Discontinued Operations on Prior Period U.S. GAAP and Adjusted Results

    BAXTER INTERNATIONAL INC. Impact of Discontinued Operations on Prior Period U.S. GAAP and Adjusted Results (unaudited, in millions) On August 12, 2024, Baxter entered into a definitive equity purchase agreement with certain affiliates of Carlyle Group Inc. to sell Baxter’s Kidney Care business, subj

  4. Slide 4: Impact of Discontinued Operations on Prior Period U.S. GAAP and Adjusted Results

    BAXTER INTERNATIONAL INC. Impact of Discontinued Operations on Prior Period U.S. GAAP and Adjusted Results (unaudited, in millions) (1) The adjusted financial measures in these schedules, which exclude the impact of special items, are non-GAAP financial measures. Refer to the tables at the end of th

  5. Slide 5: Impact of Discontinued Operations on Prior Period U.S. GAAP and Adjusted Results

    BAXTER INTERNATIONAL INC. Impact of Discontinued Operations on Prior Period U.S. GAAP and Adjusted Results (unaudited, in millions) (1) The adjusted financial measures in these schedules, which exclude the impact of special items, are non-GAAP financial measures. Refer to the tables at the end of th

  6. Slide 6: Impact of Discontinued Operations on Prior Period U.S. GAAP and Adjusted Results

    BAXTER INTERNATIONAL INC. Impact of Discontinued Operations on Prior Period U.S. GAAP and Adjusted Results (unaudited, in millions) *Totals may not foot due to rounding (1) The adjusted financial measures in these schedules, which exclude the impact of special items, are non-GAAP financial measures.

  7. Slide 7: Reconciliation of U.S. GAAP to Non-GAAP Measures: Three Months Ended June 30, 2024

    BAXTER INTERNATIONAL INC. Description of Adjustments and Reconciliation of U.S. GAAP to Non-GAAP Measures (unaudited, in millions) The company’s U.S. GAAP results, after presenting its Kidney Care business as a discontinued operation, for the three months ended June 30, 2024 included special items w

  8. Slide 8: Reconciliation of U.S. GAAP to Non-GAAP Measures: Three Months Ended March 31, 2024

    BAXTER INTERNATIONAL INC. Description of Adjustments and Reconciliation of U.S. GAAP to Non-GAAP Measures (unaudited, in millions) The company’s U.S. GAAP results, after presenting its Kidney Care business as a discontinued operation, for the three months ended March 31, 2024 included special items

  9. Slide 9: Reconciliation of U.S. GAAP to Non-GAAP Measures: Three Months Ended December 31, 2023

    BAXTER INTERNATIONAL INC. Description of Adjustments and Reconciliation of U.S. GAAP to Non-GAAP Measures (unaudited, in millions) The company’s U.S. GAAP results, after presenting its Kidney Care business as a discontinued operation, for the three months ended December 31, 2023 included special ite

  10. Slide 10: Reconciliation of U.S. GAAP to Non-GAAP Measures: Three Months Ended September 30, 2023

    BAXTER INTERNATIONAL INC. Description of Adjustments and Reconciliation of U.S. GAAP to Non-GAAP Measures (unaudited, in millions) The company’s U.S. GAAP results, after presenting its Kidney Care business as a discontinued operation, for the three months ended September 30, 2023 included special it

  11. Slide 11: Reconciliation of U.S. GAAP to Non-GAAP Measures: Three Months Ended June 30, 2023

    BAXTER INTERNATIONAL INC. Description of Adjustments and Reconciliation of U.S. GAAP to Non-GAAP Measures (unaudited, in millions) The company’s U.S. GAAP results, after presenting its Kidney Care business as a discontinued operation, for the three months ended June 30, 2023 included special items w

  12. Slide 12: Reconciliation of U.S. GAAP to Non-GAAP Measures: Three Months Ended March 31, 2023

    BAXTER INTERNATIONAL INC. Description of Adjustments and Reconciliation of U.S. GAAP to Non-GAAP Measures (unaudited, in millions) The company’s U.S. GAAP results, after presenting its Kidney Care business as a discontinued operation, for the three months ended March 31, 2023 included special items

  13. Slide 13: Reconciliation of Change in Net Sales Growth As Reported to Constant Currency

    BAXTER INTERNATIONAL INC. Reconciliation of Non-GAAP Financial Measure Change in Net Sales Growth As Reported to Constant Currency Sales Growth (1) The company's Healthcare Systems and Technologies (HST) segment was added with its acquisition of Hill-Rom Holdings, Inc. (Hillrom) in December 2021. Th

  14. Slide 14: Supplemental Historical Financial Information

    SUPPLEMENTAL HISTORICAL FINANCIAL INFORMATION N ove m b e r 7 , 2 0 24 14

Baxter International — Investor Presentation (November 2024) on 6ix